Chapter 19: Epigenetic Gene Expression Regulation

The field of epigenetics explores phenomena and mechanisms that lead to chromosome-associated, heritable changes in gene expression without altering the underlying DNA sequence, showing that the resulting phenotype arises from the interaction between the constant genome and the dynamic, cell-specific epigenome. These regulatory modifications primarily rely on three mechanisms: reversible DNA methylation, covalent histone modification, and the action of regulatory noncoding RNA (ncRNA) molecules. DNA methylation typically involves adding methyl groups to cytosines in CpG dinucleotides, especially within promoter regions, which generally results in transcriptional silencing. The patterns of methylation define the methylome, which is highly tissue-specific. Conversely, chromatin remodeling involves chemically modifying the N-terminal tails of histone proteins through processes like acetylation or methylation, with specific combinations of these marks forming the histone code that dictates whether chromatin is in an open or closed configuration, thus controlling gene accessibility for transcription. Noncoding RNAs, particularly long noncoding RNAs (lncRNAs), function as guides or adapters to deliver protein complexes and chromatin-modifying enzymes to specific genomic locations. These epigenetic processes control complex genetic events, notably monoallelic expression (MAE), where only one parental allele is transcribed; this includes genomic imprinting, which leads to parent-of-origin specific silencing implicated in disorders like Prader–Willi syndrome and Beckwith–Wiedemann syndrome, as well as the random inactivation of the X chromosome. Furthermore, epigenetic deregulation is a hallmark of cancer, characterized by global hypomethylation causing genomic instability, coupled with site-specific hypermethylation that silences key tumor-suppressor genes. Since these epigenetic changes are reversible, unlike traditional genetic mutations, researchers are developing new chemotherapy drugs that inhibit histone modifying or DNA methyltransferase enzymes to reprogram malignant cells. Lastly, the epigenome acts as the molecular interface between the external environment, including nutrition and stress, and the genome, enabling environmental factors to generate heritable changes in gene expression and behavioral traits across generations. Global initiatives, such as the International Human Epigenome Consortium, are actively mapping these modifications to better understand health and disease susceptibility.